Prucalopride (succinate) (Standard)

Prucalopride (succinate) (Standard) is the analytical standard of Prucalopride (succinate) . This product is intended for research and analytical applications. Prucalopride succinate is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer[1][2][3][4].

Product Specifications

CAS Number

[179474-85-2]

UNSPSC

12352100

Target

5-HT Receptor; Apoptosis; Autophagy; Reference Standards

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Cancer; Metabolic Disease

Smiles

O=C(O)CCC(O)=O.O=C(C1=C(OCC2)C2=C(N)C(Cl)=C1)NC3CCN(CCCOC)CC3

Molecular Formula

C22H32ClN3O7

Molecular Weight

485.96

References & Citations

[1]Briejer MR, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001 Jun 29;423 (1) :71-83.|[2]Johnson DE, et al. The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations. J Pharmacol Exp Ther. 2012 Jun;341 (3) :681-91.|[3]Wang Y, et al. Prucalopride might improve intestinal motility by promoting the regeneration of the enteric nervous system in diabetic rats. Int J Mol Med. 2022 Jul;50 (1) :87.|[4]Chen M, et al. Prucalopride inhibits lung cancer cell proliferation, invasion, and migration through blocking of the PI3K/AKT/mTor signaling pathway. Hum Exp Toxicol. 2020 Feb;39 (2) :173-181.